JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Roy Buchanan has reiterated a Market Outperform rating on Arbutus Biopharma (NASDAQ:ABUS) and maintained a $6 price target.
July 06, 2023 | 11:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arbutus Biopharma's stock rating has been reiterated as Market Outperform by JMP Securities, with a maintained price target of $6.
The reiteration of the Market Outperform rating and the maintained price target by JMP Securities indicates a positive outlook for Arbutus Biopharma. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100